Network meta-analysis on patent foramen ovale: is a stroke or atrial fibrillation worse?

Leonardo Varotto1 • Gianni Bregolin2 • Mariemma Paccanaro1 • Antonella De Boni3 • Carlo Bonanno1 • Francesco Perini3

Received: 21 September 2020 / Accepted: 18 November 2020 / Published online: 26 November 2020 © The Author(s) 2020

Abstract

Objective. Systematic reviews suggest that patent foramen ovale closure (PFOc) is performed percutaneously with low complication rates. We did a network meta-analysis (NMA) comparing devices for PFO closures, evaluating safety and efficacy of transcatheter PFOc in preventing neurological events in patients with stroke when compared with medical therapy (MT), and assessing risk of atrial fibrillation (AF).

Methods. We searched 3 databases (MEDLINE, EMBASE, CENTRAL/CCTR) identifying six randomized controlled trials from 2012 until December 2019. We performed a Bayesian NMA; number-needed-to-treat and number-needed-to-harm were derived by applying the estimated odds ratios (ORs). The likelihood of being helped or harmed (LHH) was evaluated to estimate the risk-effectiveness balance.

Results. The 3560 patients allocated to PFOc were less subject to a stroke than patients with MT. The overall ORs of PFOc versus MT were 0.41 with fixed-effects, and 0.22 with random-effects model. NMA proves that PFOc induces AF episodes significantly higher than MT, even when analysis is limited to only new episodes of “serious AF.” LHH (0.68 fixed-effects, 0.79 random-effects) showed that strokes saved are less than cases of AFs added. By considering only serious AF, strokes saved are higher than serious AFs induced by the PFOc (LHH was 3.46 and 4.00 respectively).

Conclusions. NMA supported PFOc in patients with cryptogenic stroke, confirming that devices are better than MT, but increase the risk of AF by over 2/4 times (serious or unserious AF). Considering serious AFs (real risky clinical condition), patients have more advantages in being treated, since LHH is ≥3–4.

Keywords. Cryptogenic • PFO or patent foramen ovale • Ischemic stroke or cerebrovascular accident • Transient ischemic attack or TIA • Paradoxical embolism

Introduction

Ischemic stroke is one of the leading causes of death and disability worldwide. Fundamental to the management of stroke patients is the prevention of further ischemic events.

This rule applies especially to patent foramen ovale (PFO)-related stroke in young patients.

Many meta-analyses suggest that PFO closure can be performed percutaneously with generally low complication rates, but have shown that PFO closure increases the risk of atrial fibrillation (AF) [1–5].

Most cases of AF in the randomized controlled trials (RCTs) occurred early after implantation and consisted of a single paroxysmal episode, that resolved spontaneously, medically, or with cardioversion. Only 3.8% of post-closure AF episodes reportedly progress to permanent AF [6, 7].

Many observations have also stated that the new-onset of AF after PFO closure depends on the type of device used and that the Amplatzer device seems to appear better in preventing episodes of AF, when compared to other devices [8–11].

In the six published RCTs [3, 4, 12–16], 11 different devices were used.
We did a network meta-analysis (NMA) by comparing devices, so as to evaluate the safety and efficacy of transcatheter PFO closure in the prevention of recurring ischemic strokes, in patients with cryptogenic stroke when compared with medical therapy (MT). We sought also to systematically assess the incidence and the risk of new-onset AF in the same patients, evaluating the severity of AF episodes, as reported by the authors of the RCTs.

We therefore performed a NMA to investigate device-specific differences and results, to allow a unified and consistent comparison between groups of different devices.

**Methods**

**Strategy and selection criteria**

This meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses Protocols (PRISMA-P) statement [17] (Supplementary Figure 1, where the databases and keywords used are also listed).

The study protocol was registered with PROSPERO: CRD42020157003.

Data extraction was performed by two independent investigators (LV, CB) and any discrepancies were resolved by a third author (MP). All selected papers were required to be RCTs comparing experimental and different approved transcatheter PFO closure devices with MT. After examining 497 studies, we identified 6 RCTs through a literature search from 2012 until December 31, 2019, that assessed the efficacy of transcatheter PFO closure for secondary prevention of cryptogenic strokes or TIA, compared to MT. The four groups of devices investigated in randomized trials were Amplatzer PFO Occluder (AMP, Abbott, Chicago, IL, USA), STARFlex Septal Occluder (STF, NMT Medical, Boston, MA, USA), Gore HELEX Septal Occluder/Gore Cardioform Septal Occluder (HLX/CF, W.L. Gore and Associates, Flagstaff, AZ, USA), and a group in which a variety of eleven devices were used during the CLOSE trial [3] (including 238 patients allocated to PFO closure—MIXED devices—, of which 138 with AMP).

**Data collection**

We extracted information on study design, outcomes, characteristics of patients, length of follow-up, and components of methodological quality, including concealment of allocation, independent event adjudication, and analysis according to the intention-to-treat principle [18–20]. If multiple reports were available for one trial, we used information of all reports for data extraction, but extracted outcome data only once, based on the intention-to-treat principle and the longest follow-up available. The primary outcome measures of this analysis were recurrences of ischemic stroke. Secondary endpoints included new-onset AF. With the exception of the STF device that had a significantly lower procedural success rate and more pronounced new-onset AFs, we evaluated the remaining devices similarly, in relation to demonstration of a high and comparable frequency of success or risk of new-onset AF.

The cases of new-onset AF have been considered “serious” or because defined by the authors as such or because they were persistent. Late-onset AF was defined as AF occurring > 45 days post-PFO closure. For a correct comparison of the data, we reported all AFs and not only those defined as “serious”, published in RESPECT [15]. The data used for AMP were derived from the new Instruction For Use relating to the January 2018 device, updated by St. Jude Medical in order to collect the extended follow-up of the RESPECT study (data equal to those used to obtain the 2016 FDA approval).

The data were double-checked and the consensus reached to avoid disagreement. We contacted the authors of one RCT for additional data [9].

**Risk of bias**

We assessed risk of bias in duplicate using a modified Cochrane Collaboration tool [21]. For each of the seven risk dimensions analyzed, we assigned a low, a moderate, or a high risk of bias to the studies. Reviewers resolved conflicts through discussion. The overall internal validity was considered a whole at “low risk of bias” (Supplementary Figure 2).

**Statistical analysis**

To compare the effects of alternative PFO closure with devices versus MT, for ischemic stroke (primary outcome) and recurrent AF (secondary outcomes), we conducted a NMA of RCTs within a Bayesian hierarchical fixed and random-effect framework with non-informative priors to derive the posterior distribution [22]. We used pooled ORs with credible intervals (Cr.Is) 95% as statistical indicator.

Analyses were done in NetMetaXL 1.6. [23] and WinBUGS 1.4. These programs provide the summary tables, the network diagram, the forest plot, the league table, the ranking list with SUCRA (Surface Under the Cumulative RAnking curve) indicator, and heterogeneity. We evaluated convergence using the Brooks-Gelman-Rubin method.

We also assessed inconsistency by comparing deviation residues and statistics of deviance information criteria. Inconsistency plots assessing network inconsistencies between direct and indirect estimates showed a low possibility that the inconsistencies may significantly affect the network meta-analysis results (Supplementary Figure 3 and Supplementary Figure 4).
Neither the heterogeneity index, nor the qualitative/visual analysis of the funnel plot produced in the exploratory phase, nor much less the analysis of inconsistency has raised the suspicion that the trials cannot be compared and analyzed jointly in order to produce a synthesis result.

Numbers-needed-to-treat (NNT) and number-needed-to-harm (NNH) were derived by transforming the estimated odds ratios (ORs). The likelihood of being helped or harmed (LHH) was evaluated to estimate the risk-effectiveness balance [24].

**Results**

Four hundred and ninety-seven records were found by searching databases and trial registers until the end December 2019. Six randomized, multicenter, controlled open-label trials (with blinded adjudication of outcome events) were identified (Supplementary Table 1).

Accordingly, the six trials [3, 4, 12–16] and 3560 patients (the mean age was 45.4 to 46.2 years) with cryptogenic stroke and PFO were included in the review and NMA, with four treatment groups with devices versus MT, to study the efficacy of PFO closure for secondary prevention. The mean follow-up period of all 6 RCTs was 2 to 5.9 years. Baseline characteristics and events in the RCTs are reported in Supplementary Table 2.

Three trials compared PFO closure with AMP versus MT (group AMP), one PFO closure with STF versus MT (group STF), and one PFO closure with HLX/CF versus MT (group HLX/CF). The CLOSE Trial used 11 devices, and 238 patients were assigned to the PFO closure versus the antiplatelet-only therapy. We have created a subgroup by extrapolating 138 patients treated with three types of AMP (Septal Occluder, Cribriform and Atrial Septal Device) during stroke analysis and moved them to the AMP group, which concerns a total of 901 patients included in 4 trials. The other 100 patients for CLOSE trial remained in a group with 8 different devices (group MIXED devices) and were compared with MT. Figure 1 shows the network of evidence.

Patients allocated to PFO closure were significantly less likely to experience a stroke compared with patients allocated to MT. From NMA, the ORs for any device versus MT were 0.41 (Cr.I. 95%, 0.27–0.60) with fixed-effects model and 0.22 (Cr.I. 95%, 0.05–0.70) with random-effects model (Fig. 2).

The patients allocated to the AMP group had similar risk as patients with HLX/CF group or with group of 8 mixed devices (MIX). The AMP device proves to be more variable in terms of results (between fixed and random effects) as regards its effectiveness in containing further strokes, with results similar to the HLX/CF device, suggesting their equality.

However, in our NMA, PFO closure increased the risk of new-onset AF. The NMA demonstrated that MT induces a number of AF episodes significantly less than all the devices (OR 0.20 fixed-effects, 95% Cr.I., 0.11–0.32; OR 0.17 random-effects, Cr.I. 95% 0.05–0.39) (Fig. 3).

The risk of causing an AF is just over 4 times higher than in MT (risk ratio = 4.10, 95% CI. 2.43–6.92).

In favor of the AMP, there would be a greater containment of cases of AF vs MT, compared to HLX/CF, but not the superiority of a device compared to this or another device when we use the random-effect model.

The same trend is obtained if we consider only the episodes of AF defined as serious (OR 0.43 fixed-effects, 95% Cr.I., 0.2–0.88; OR 0.40 random-effects, Cr.I. 95% 0.11–1.04), but
**Fig. 2** Bayesian comparison between treatments: stroke’s events. Legend: Forest plot and odds ratio estimated with 95% credible interval, fixed, and random model. The AMP’s relevance is 19/901 = 2.1% (events/patients); STF 12/447 = 2.7%; HLX/CF 6/441 = 1.4%; MIX 0/100 = 0%; MT 77/1671 = 4.6%. MT, medical therapy; HLX/CF, Helex/Cardioform; MIX, mixed devices; AMP, Amplatzer; STF, Starflex; Cr.I., credible interval; OR, odds ratio.

| Treatment 1 vs Treatment 2 | Fixed Effects | Random Effects |
|---------------------------|--------------|---------------|
|                           | O.R. Median  | O.R. Median   |
|                           | (95% Cr.I.)  | (95% Cr.I.)   |
| AMP - MT                  | 0.38         | 0.15          |
| STF - MT                  | 0.95         | 0.95          |
| HLX/CF - MT               | 0.24         | 0.23          |
| MIX - MT                  | 0.08         | 0.09          |
| AMP - STF                 | 0.40         | 0.16          |
| HLX/CF - AMP              | 0.63         | 1.54          |
| MIX - AMP                 | 0.21         | 0.62          |
| HLX/CF - STF              | 0.25         | 0.24          |
| MIX - STF                 | 0.08         | 0.09          |
| MIX - HLX/CF              | 0.34         | 0.37          |
| Any device - MT           | 0.41         | 0.22          |

Heterogeneity = 1.32; 95% Cr.I. (0.44 – 1.96)

**Fig. 3** Bayesian comparison between treatments: atrial fibrillation (all events). Legend: Forest plot and odds ratio estimated with 95% credible interval, fixed, and random model. The AMP’s relevance is 36/901 = 4% (events/patients); STF 23/447 = 5.1%; HLX/CF 29/441 = 6.6%; MIX 7/100 = 7%; MT 17/1671 = 1%. AF, atrial fibrillation; MT, medical therapy; HLX/CF, Helex/Cardioform; MIX, mixed devices; AMP, Amplatzer; STF, Starflex; Cr.I., credible interval; OR, odds ratio.

| Treatment 1 vs Treatment 2 | Fixed Effects | Random Effects |
|---------------------------|--------------|---------------|
|                           | O.R. Median  | O.R. Median   |
|                           | (95% Cr.I.)  | (95% Cr.I.)   |
| MT - AMP                  | 0.33         | 0.29          |
| MT - STF                  | 0.11         | 0.11          |
| MT - HLX/CF               | 0.04         | 0.04          |
| MT - MIX                  | 0.12         | 0.11          |
| AMP - STF                 | 0.33         | 0.36          |
| AMP - HLX/CF              | 0.13         | 0.15          |
| AMP - MIX                 | 0.37         | 0.38          |
| STF - HLX/CF              | 0.40         | 0.40          |
| MIX - STF                 | 0.89         | 0.96          |
| MIX - HLX/CF              | 0.35         | 0.38          |
| MT - Any Device           | 0.20         | 0.17          |

Heterogeneity (Vague) = 0.61; 95% Cr.I (0.03 – 1.78)
the risk of causing an AF with PFO closure versus MT is halved (risk ratio = 2.26, 95% C.I. 1.1–4.65) (Fig. 4).

The estimated NNT to prevent one stroke for PFO closure compared with MT was 37 (Cr.I. 95%, 30–57) with fixed-effects model and 28 (Cr.I. 95%, 23–75) with random-effects model; the NNH to cause one case of new-onset AF for PFO closure versus MT was 25 (95% Cr.I. 14–49) with fixed-effects model and 22 (Cr.I. 95%, 7–66) with random-effects model (Table 1).

The LHH was 0.68 and 0.79, respectively, and showed that the number of strokes saved is less than that of AF added. If we calculate this parameter considering only the serious AF, the number of strokes saved is higher than that of serious AF induced by the PFO closure (LHH was 3.46 and 4.00 respectively) (Fig. 5).

We have performed a summary comparison between the two most used devices through a bidimensional analysis.

In order to visualize the performances of the two main devices in use relating to the two significant events (stroke and AF), a two-dimensional graph has been built which highlights once again that (1) both devices are not substantially different from each other (they remain very close to each other in the fourth quadrant); (2) AMP has better joint median performances (considering both aspect of AF and of stroke), but not for this statistical difference with respect to HLX/CF; (3) the better performance of AMP is mainly linked to the greater containment of AF events, and the result is slightly amplified when the method of analysis adopted is that of random effects; and (4) this performance remains of the same proportion when analyzing serious AF (Fig. 6).

Discussion

A recent meta-analysis [7] shows that, among the new-onset AFs following percutaneous PFO closure, only <25% of new-onset AFs become persistent. These AFs could either be primary AFs or device-related AFs, called “therapeutic failure.” The pooled incidence of stroke presumably caused by device-associated AF in the PFO closure group was 0.1%.

Catheter manipulation and wires crossing through the left atrium during closure device deployment can trigger AF.

Some cases of reduction in the incidence of AF with the closure of the foramen ovale have been described [25] (probably due to the reduction of the atrial vulnerability to arrhythmias of the hypermobile interatrial septum, especially when associated with an atrial septal aneurysm [26], or to the decrease of the mechanical stretching of the atrium due to the presence of intermittent interatrial shunting [27, 28]). However, as explained [5], the stretch or septal irritation

---

**Fig. 4** Bayesian comparison between treatments: atrial fibrillation (serious events). Legend: Forest plot and odds ratio estimated with 95% credible interval, fixed, and random model. The AMP’s relevance is 10/901 = 1.1% (events/patients); STF 6/447 = 1.3%; HLX/CF 10/441 = 2.3%; MIX 0/100 = 0%; MT 10/1671 = 0.6%. AF, atrial fibrillation; MT, medical therapy; HLX/CF, Helex/Cardioform; MIX, mixed devices; AMP, Amplatz; STF, Starflex; Cr.I., credible interval; OR, odds ratio.
### Table 1  Measures of effectiveness and undesirability of PFO closure versus medical therapy

| Treatment/device | NNT - stroke | NHH - all events | NHH - serious |
|------------------|--------------|------------------|---------------|
|                  | Median value (95% Cr.I.) | Median value (95% Cr.I.) | Median value (95% Cr.I.) |
| **Fixed effects approach** | | | |
| AMP | 35 (28–61) | 49 (21–156) | 210 (39–∞) |
| STF | 411 (38–∞) | 13 (3–49) | 141 (17–∞) |
| HLX/CF | 29 (24–59) | 6 (1–35) | 28 (2–∞) |
| MIX | 22 (22–42) | 15 (5–69) | 12 (1–∞) |
| **Total** | 37 (30–57) | 25 (14–49) | 128 (42–1185) |
| **Random-effects approach** | | | |
| AMP | 26 (22–67) | 42 (9–463) | 156 (13–∞) |
| STF | 489 (23–∞) | 13 (2–575) | 137 (7–∞) |
| HLX/CF | 29 (22–∞) | 5 (1–97) | 28 (2–∞) |
| MIX | 22 (22–∞) | 13 (2–258) | 10 (1–∞) |
| **Total** | 28 (23–75) | 22 (7–66) | 112 (21–∞) |

In the table are shown the median value of NNH (number-needed-to-harm) and NNT (number-needed-to-treat) for fixed and random approach, as measures of clinical outcomes in the PFO closure versus medical therapy. The NNH value is calculated both for all atrial fibrillation events and for serious events only.

**AMP**, Amplatzer; **STF**, Starflex; **HLX/CF**, Helex/Cardioform; **MIX**, mixed devices; **PERR**, patient-expected event rate; **OR**, odds ratio

\[
NNT = \frac{1-(PEER*(1-OR))}{((1-PEER)*(PEER)*(1-OR))}
\]

\[
NNH = \frac{(PEER*(OR-1)) + 1}{(PEER*(OR-1))*((1-PEER))}
\]

**Fig. 5** Measures of effectiveness and undesirability of PFO closure versus MT therapy. Legend: In the four graphs are shown the median value of NNH (number-needed-to-harm), NNT (number-needed-to-treat), and its ratio LHH (likelihood of being helped or harmed), for fixed and random approach, as measures of clinical outcomes in the PFO closure versus medical therapy. In one case, all the events of atrial fibrillation (AF) are examined; in the other, only serious AF. AMP, Amplatzer; HLX/CF, Helex/Cardioform; MIX, mixed devices; STF, Starflex, TOT, total value from combined devices.
during and after device deployment can determine a further clinical risk for the patient, which should not be underestimated.

In this work, we wanted to try to reach an effective shared decision-making parameter, proposing a patient-centered measure, i.e., evaluating the probability that a patient could be either helped or harmed by the intervention of percutaneous closure of the foramen ovale. This leaves the discussion open to the evaluation of the usefulness of this procedure and stimulates further investigations.

Apparently, from the clinical point of view, the impact of a stroke compared to a new onset of atrial fibrillation is not the same, but the patient must know by informed consent what may happen and know above all that decision-making processes are developed at the bedside to identify the best therapeutic decisions. The statistical tools are there and have helped us to express the useful and harmful effects of the percutaneous treatment and modify the statements according to the patient’s wishes.

From our NMA, the incidence of AF with devices currently on the market is slightly different, but not significantly different. While we have a duty to analyze well the possible presence of a primary AF with adequate pathways and according to standardized protocols [29], without having to hurry to perform a percutaneous PFO closure, we must also consider that the onset of a

---

**Fig. 6** Bidimensional analysis of comparisons between treatments, atrial fibrillation, and stroke. Legend: The graph shows the estimated odds ratio (median value) and 95% Cr.I. with the Bayesian method for the Amplatz and Helex/Cardioform devices in comparison with MT. The more the device has a position oriented towards the lower left corner, the more it is effective in containing stroke and AF events compared to MT. The red dotted lines indicate how this result is obtained from the two devices. As we can see, at the current state of knowledge, the best performances are attributed to the Amplatz device by virtue of its greater containment of AF events. However, we cannot confirm that this difference in performance is statistically significant. The credibility intervals, indeed, overlap.

AF, Atrial Fibrillation; AMP, Amplatz; HLX/CF, Helex/Cardioform; LHH, Likelihood of Being Helped or Harmed; MT, Medical Therapy; PFO, percutaneous patent foramen ovale; vs, versus.
device-related AF should not be classified as “therapeutic failure,” at least for devices currently in use and with the data in our possession. Furthermore, if the new (practically absent) ischemic events caused by serious AF could be deduced from the benefit of preventing ischemic events with percutaneous closure of the foramen ovale, AF after closure of the foramen ovale could be regarded as a non-event.

There are some limitations in our NMA. Because the studies analyzed in our NMA defined cryptogenic stroke after excluding primary AF based on short-term conventional monitoring or repeated electrocardiograms, our NMA may also have included some cardioembolic strokes related to not yet fully developed methods or insufficient investigations. Therefore, some AF, which appeared after implanting the device, may not be of first/new-onset.

However, the overall incidence of follow-up AF in the included trials of our NMA was less than previously reported [30]. A precise and careful algorithm for diagnostic workup of cryptogenic left circulation thromboembolism in the next randomized studies (with the aid of loop recorder or patch-based and water-resistant cardiac patch rhythm monitor) [29, 31], associated with better devices and refinement of implantation techniques perhaps will provide us with more precise answers. In this way, the true onset of atrial arrhythmia after implantation of the device could be more clearly evaluated and highlighted, even in asymptomatic patients.

In addition, data could be analyzed in terms of the influence of the age of patients presenting with post-procedural AF, since the importance and risk of AF arising in patients under 40 years old is not the same as that of AF occurring over 40 years.

Further randomized studies seem not be easy, but certainly in general clinical practice, after having well excluded the cases of primary AF and after PFO closure, it will probably be necessary once again to define and differentiate all AFs from those that are persistent or defined as serious. In fact, the clinical significance of excluding the episodes of transient AF device-related, maintaining only the serious AFs, modifies clearly the risk-benefit balance for the patient.

Conclusions

Our NMA provides evidence in favor of PFO closure with all the devices used in young patients with cryptogenic stroke and PFO. We can presently conclude that these devices are better than MT, but increase the risk of AF by over 4 times if we consider all cases of AFs and only 2 times with serious AF. We cannot state that one device is better than the rest (AMP has the best performance but is not statistically superior to HLX/C) to reduce AF episodes in the follow-up. Considering serious AFs (real risky clinical condition), patients have more advantages in being treated than in not being, since LHH is ≥ 3–4. Which then is the lesser of two evils?

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s10072-020-04922-4.

Compliance with ethical standards

Conflict of interest None.

Statement of informed consent No patients were involved in this study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Mojadidi MK, Elgendy AY, Elgendy IY, Mahmoud AN, Elbadawi A, Eshtehardi P, Patel NK, Wayangankar S, Tobis JM, Meier B (2017) Transcatheter patent foramen ovale closure after cryptogenic stroke: an updated meta-analysis of randomized trials. JACC Cardiovasc Interv 10:2228–2230. https://doi.org/10.1016/j.jcin.2017.09.002
2. Mojadidi MK, Zaman MO, Elgendy IY, Mahmoud AN, Patel NK, Agarwal N, Tobis JM, Meier B (2018) Cryptogenic stroke and patent foramen ovale. J Am Coll Cardiol 71:1035–1043. https://doi.org/10.1016/j.jacc.2017.12.059
3. Mac JL, Derumeaux G, Guillot B, Massardier E, Hosseini H, Mechtoulif L, Arquianzan C, Béjot Y, Vuillier F, Detante O, Guidoux C, Canaple S, Vaudva C, Dequatre-Ponchelle N, Sibon I, Garnier P, Ferrier A, Timsit S, Robinet-Borgomano E, Sablot D, Lacour JC, Zuber M, Favrole P, Pinel JE, Aplin M, Reiner P, Lefebvre C, Guériou P, Piot C, Rossi R, Dubois-Randé JL, Eicher JC, Meneveau N, Lusson JR, Bertrand B, Schleim JM, Godart F, Thambo JB, Leborgne L, Michel P, Pierard L, Turc G, Barthelet M, Charles-Nelson A, Weimar C, Moulin T, Juliard JM, Chatellier G, Investigators CLOSE (2017) Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. CLOSE Investigators. N Engl J Med 377:1011–1021. https://doi.org/10.1056/NEJMoa1705915
4. Sondergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-Kudsk JE, Settgren M, Sjöstrand C, Roine RO, Hildick-Smith D, Spence JD, Thomassen L, Gore REDUCE Clinical Study Investigators (2017) Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. Gore REDUCE Clinical Study Investigators. N Engl J Med 377:1033–1042. https://doi.org/10.1056/NEJMoa1707404
5. Stortechy S, da Costa BR, Mattle HP, Carroll J, Hormung M, Sievert H, Trelle S, Windecker S, Meier B, Jüni P (2015) Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis. Eur Heart J 36:120–128. https://doi.org/10.1093/eurheartj/ehu292
6. Staubach S, Steinberg DH, Zimmermann W, Wawra N, Wilson N, Wunderlich N, Sievert H (2009) New onset atrial fibrillation after
7. Elgendy AY, Elgendy IY, Mojaddidi MK, Mahmoud AN, Barry JS, Jneid H, Wayangankar SA, Tobs JM, Meier B (2019) New-onset atrial fibrillation following percutaneous patent foramen ovale closure: a systematic review and meta-analysis of randomised trials. EuroIntervention 14:1788–1790. https://doi.org/10.4244/EIJ-D-18-00767

8. Taaffe M, Fischer E, Baranowski A, Majunke N, Heinisch C, Leetz M, Hein R, Bayard Y, Büscheck F, Reschke M, Hoffmann I, Wunderlich N, Wilson N, Sievert H (2018) Comparison of three patent foramen ovale closure devices in a randomized trial (Amplatzer versus CardioSEALSTARflex versus Helex occluder). Am J Cardiol 101:1353–1358. https://doi.org/10.1016/j.amjcard.2007.12.040

9. Ture G, Calvet D, Guérin P, Stroussi M, Chatellier G, Mas JL, CLOSE Investigators (2018) Closure, anticoagulation, or antiplatelet therapy for cryptogenic stroke with patent foramen ovale: systematic review of randomized trials, sequential meta-analysis, and new insights from the CLOSE Study. J Am Heart Assoc e008356. https://doi.org/10.1161/JAHA.117.008356

10. Madhkour R, Wahl A, Praz F, Maier B (2019) Amplatzer patent foramen ovale occluder: safety and efficacy. Expert Rev Med Devices 16:173–182. https://doi.org/10.1080/17434440.2019.1581060

11. Hornung M, Bertog SC, Franke J, Id D, Taaffe M, Wunderlich N, Vaskelyte L, Hofmann I, Sievert H (2013) Long-term results of a randomized trial comparing three different devices for percutaneous closure of a patent foramen ovale. Eur Heart J 34:3362–3369. https://doi.org/10.1093/eurheartj/het283

12. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, Felberg R, Herrmann H, Kar S, Landzberg M, Raizner A, Wechsler L, CLOSURE I Investigators (2012) Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 366:A1790. doi.org/10.1056/NEJMoa1211716

13. Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, Andersen G, Ibrahim R, Schulier G, Walton AS, Wahl A, Windecker S, Jüni P, Trial Investigators PC (2013) Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 368:1083–1091. https://doi.org/10.1056/NEJMoa1211716

14. Carroll JD, Saver JL, Thaler DE, Smallling RW, Berry S, MacDonald LA, Marks DS, Tirschwell DL, RESPECT Investigators (2013) Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 368:1092–1100. https://doi.org/10.1056/NEJMoa1301440

15. Saver JL, Carroll JD, Thaler DE, Small OW, MacDonald LA, Marks DS, Tirschwell DL, RESPECT Investigators (2017) Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med 377:1022–1032. https://doi.org/10.1056/NEJMoa1600507

16. Lee PH, Song JK, Kim JS, Heo R, Lee S, Kim DH, Song JM, Kang DH, Kwon SU, Kang DW, Lee D, Kwon HS, Yun SC, Sun BJ, Park JH, Lee JH, Jeong HS, Song HJ, Kim J, Park SJ (2018) Diagnostic yield of extended cardiac patch monitoring in patients with patent foramen ovale. Comparison of three different devices for percutaneous closure of a patent foramen ovale. Catheter Cardiovasc Interv 74:899–905. https://doi.org/10.1002/ccd.22172

17. Elgendy AY, Elgendy AY, Mojaddidi MK, Mahmoud AN, Barry JS, Jneid H, Wayangankar SA, Tobs JM, Meier B (2019) New-onset atrial fibrillation following percutaneous patent foramen ovale closure: a systematic review and meta-analysis of randomised trials. EuroIntervention 14:1788–1790. https://doi.org/10.4244/EIJ-D-18-00767

18. Jüni P, Altman DG, Egger M (2001) Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 323:42–46. https://doi.org/10.1136/bmj.323.7303.42

19. Savovic J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, Alsnielson B, Balk EM, Gruud C, Gruud LL, Ioanidip JS, Schulz KF, Beynon R, Welton NJ, Wood L, Moher D, Deeks JJ, Sterne JA (2012) Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med 157:429–438. https://doi.org/10.7326/0003-4819-157-6-201209180-00537

20. Page MJ, Higgins JP, Clayton G, Sterne JA, Hróbjartsson A, Savovic J (2016) Empirical evidence of study design biases in randomized trials: systematic review of meta-epidemiological studies. PLoS One 11:e0159267. https://doi.org/10.1371/journal.pone.0159267

21. Higgins JP, Altman DG, Gotzsche PC et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https://doi.org/10.1136/bmj.d5928

22. Lu G, Ades AE (2004) Combination of direct and indirect evidence in mixed treatment comparison. Stat Med 23:3105–3124. https://doi.org/10.1002/sim.1875

23. Brown S, Hutton B, Clifford T, Coyle D, Grima D, Wells G, Cameron C (2014) A Microsoft-Excel-based tool for running and critically appraising network meta-analyses—an overview and application of NetMetaXL. Syst Rev 3:110. https://doi.org/10.1186/2046-4053-3-110

24. Strauss SE (2002) Individualizing treatment decisions. The likelihood of being helped or harmed. Eval Health Prof 25:210–224. https://doi.org/10.1177/01675269022500206

25. Jarral OA, Saa A, Vecht JA, Harling L, Rao C, Ahmed K, Gatzoulis MA, Malik IS, Athanasius T (2011) Does patent foramen ovale closure have an anti-arrhythmic effect? A meta-analysis. Int J Cardiol 153:4–9. https://doi.org/10.1016/j.ijcard.2011.02.027

26. Berthet K, Lavergne T, Cohen A, Guizé L, Bousser MG, Le Huezey JY, Amarencop P (2000) Significant association of atrial vulnerability with atrial septal abnormalities in young patients with ischemic stroke of unknown cause. Stroke 31:398–403. https://doi.org/10.1161/01.str.31.2.398

27. Allecsia MA, Boyden PA, Camm AJ, Kléber AG, Lab MJ, Legato MJ, Morgan CA, Rymer MM, Thijs V, Rogers T, Beckers F, Lindborg K, Brachmann J, CRYSTAL AF Investigators (2014) Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 370:2478–2486. https://doi.org/10.1056/NEJMoa1313600

28. Frans MR (2000) Mechano-electrical feedback. Cardiovasc Res 45:263–266. https://doi.org/10.1016/S0008-6363(99)00390-9

29. Pristipino C, Sievert H, D’Ascenzo F, Mas JL, Meier B, Sciacca F, Hildick-Smith D, Gaia F, Toni D, Kyrle P, Thomson J, Derumeaux G, Maronec O, Sibbing D, Germonpré P, Berti S, Chessa M, Bedogni F, Dudek D, Hornung M, Zamorano J, European Association of Percutaneous Cardiovascular Interventions (EAPCI); European Stroke Organisation (ESO); the European Heart Rhythm Association (EHRA); European Association for Cardiovascular Imaging (EACVI); Association for European Paediatric and Congenital Cardiology (AEPC); ESC Working Group on GUCH; ESC Working Group on Thrombosis; European Haematological Society (EHA) (2019) European position paper on the management of patients with patent foramen ovale. General approach and left circulation thrombembolism. EuroIntervention 14:1389–1402. https://doi.org/10.4244/EIJ-D-18-00622

30. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, Rymyer MM, Thijs V, Rogers T, Beckers F, Lindborg K, Brachmann J, CRYSTAL AF Investigators (2014) Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 370:2478–2486. https://doi.org/10.1056/NEJMoa1313600

31. Tung CE, Derek Su D, Turakhia MP, Lansberg MG (2015) Diagnostic yield of extended cardiac patch monitoring in patients with stroke or TIA. Front Neurol 5:266. https://doi.org/10.3389/fneur.2014.00266

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.